Timothy S. Pardee, MD | Authors

Articles

Initial Results from the CALGB 10801 Study

May 14, 2014

Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).

The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies

February 06, 2014

Timothy S. Pardee, MD, from Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.